PMID- 38414743
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240229
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 14
DP  - 2024
TI  - A new, potential and safe neoadjuvant therapy strategy in epidermal growth factor 
      receptor mutation-positive resectable non-small-cell lung cancer-targeted 
      therapy: a retrospective study.
PG  - 1349172
LID - 10.3389/fonc.2024.1349172 [doi]
LID - 1349172
AB  - BACKGROUND: Studies of epidermal growth factor receptor (EGFR) tyrosine kinase 
      inhibitors (TKIs) in resectable non-small-cell lung cancer (NSCLC) have been 
      conducted. The purpose of our study was to evaluate the benefits of osimertinib 
      as neoadjuvant therapy for resectable EGFR-mutated NSCLC. METHOD: This 
      retrospective study evaluated patients with EGFR mutations in exon 19 or 21 who 
      received targeted therapy with osimertinib (80 mg per day) before surgery between 
      January 2019 and October 2023 in Henan Cancer Hospital. RESULTS: Twenty patients 
      were evaluated, all of whom underwent surgery. The rate of R0 resection was 100% 
      (20/20). The objective response rate was 80% (16/20), and the disease control 
      rate was 95% (19/20). Postoperative pathological analysis showed a 25% (5/20) 
      major pathological response rate and 15% (3/20) pathological complete response 
      rate. In total, 25% (5/20) developed adverse events (AEs), and the rate of grades 
      3-4 AEs was 10% (2/20). One patient experienced a grade 3 skin rash, and 1 
      patient experienced grade 3 diarrhea. CONCLUSION: Osimertinib as neoadjuvant 
      therapy for resectable EGFR-mutated NSCLC is safe and well tolerated. Osimertinib 
      has the potential to improve the radical resection rate and prognosis.
CI  - Copyright (c) 2024 Liu, Liu, Xing, Ma, Lv, Zheng and Xing.
FAU - Liu, Baoxing
AU  - Liu B
AD  - Department of Thoracic Surgery, The Affiliated Cancer Hospital of Zhengzhou 
      University, Henan Cancer Hospital, Zhengzhou, China.
FAU - Liu, Xingyu
AU  - Liu X
AD  - Department of Thoracic Surgery, The Affiliated Cancer Hospital of Zhengzhou 
      University, Henan Cancer Hospital, Zhengzhou, China.
FAU - Xing, Huifang
AU  - Xing H
AD  - Department of Geriatric Medicine, The First Affiliated Hospital of Zhengzhou 
      University, Zhengzhou, Henan, China.
FAU - Ma, Haibo
AU  - Ma H
AD  - Department of Thoracic Surgery, The Affiliated Cancer Hospital of Zhengzhou 
      University, Henan Cancer Hospital, Zhengzhou, China.
FAU - Lv, Zhenyu
AU  - Lv Z
AD  - Department of Thoracic Surgery, The Affiliated Cancer Hospital of Zhengzhou 
      University, Henan Cancer Hospital, Zhengzhou, China.
FAU - Zheng, Yan
AU  - Zheng Y
AD  - Department of Thoracic Surgery, The Affiliated Cancer Hospital of Zhengzhou 
      University, Henan Cancer Hospital, Zhengzhou, China.
FAU - Xing, Wenqun
AU  - Xing W
AD  - Department of Thoracic Surgery, The Affiliated Cancer Hospital of Zhengzhou 
      University, Henan Cancer Hospital, Zhengzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20240213
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC10897038
OTO - NOTNLM
OT  - epidermal growth factor receptor
OT  - neoadjuvant targeted therapy
OT  - non-small cell lung cancer
OT  - osimertinib
OT  - resectable
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2024/02/28 06:45
MHDA- 2024/02/28 06:46
PMCR- 2024/01/01
CRDT- 2024/02/28 03:50
PHST- 2023/12/04 00:00 [received]
PHST- 2024/01/29 00:00 [accepted]
PHST- 2024/02/28 06:46 [medline]
PHST- 2024/02/28 06:45 [pubmed]
PHST- 2024/02/28 03:50 [entrez]
PHST- 2024/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2024.1349172 [doi]
PST - epublish
SO  - Front Oncol. 2024 Feb 13;14:1349172. doi: 10.3389/fonc.2024.1349172. eCollection 
      2024.